Drugs / Autologous Adoptive immune cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05438342 | Nov 2021 → Oct 2023 | cancer of unknown primary site, metastatic malignant neoplasm | Shanghai Pudong Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Adoptive immune cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05438342 ↗ |
| Modality | Cell therapy | “cultured adoptive immune cells” NCT05438342 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT05438342 ↗ |